Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. - Stewart AK; Krishnan AY; Singhal S; Boccia RV; Patel MR; Niesvizky R; Chanan-Khan AA; Ailawadhi S; Brumm J; Mundt KE; Hong K; McBride J; et al. (Blood cancer journal, 2019)